NCT05787561View on ClinicalTrials.gov

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Mesonephric Gynecologic Cancer
Interventions
DRUG

Avutometinib (VS-6766)

3.2 mg PO, twice weekly

DRUG

Defactinib

200 mg PO BID for 3 weeks, followed by a 1 week rest period, in each 4-week (28 day) cycle.

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk -Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
collaborator

Verastem, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER